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There is much evidence (1-4) suggesting that a high concentration of serum 
cholesterol is an important factor in the etiology of atherosclerosis. It remains to 
be demonstrated, however, that therapeutic reduction in the serum level of this 
lipid will decrease the rate of formation, or cause dissolution of atheromata h 
man. In order to carry out such investigations, procedures for sustained depres- 
sion of high cholesterol levels by tolerable means must be available. Nicotinic 
acid administered in large doses has been found to be an effective method in 
both clinical (5-8) and animal (9) studies. One of the drawbacks to using this 
form of therapy, however, has been the occurrence of uncomfortable side effects. 
Flushing, pruritus, and gastric irritation have been troublesome, especially early 
in the course of treatment. For this reason, attempts have been made to modify 
the drug in such a way as to eliminate its side effects while retaining its cho- 
lesterol-lowering potency. The purpose of this report is to present the results of a 
clinical investigation of one such drug modification, aluminum nicotinatel. 
MATERIAL AND METHODS 
Twenty-five patients with hypercholesterolemia, most of them with clinical manifesta- 
tions of atherosclerosis, were studied on an out-patient basis. The group consisted of 12 
females and 13 males. Patients were selected simply on the basis of demonstrated hyper- 
cholesterolemia and willingness to enter into an experimental situation requiring regular 
visits and serum cholesterol determinations. 
Serum cholesterol concentration was determined by a modification of the method of 
Zak (10). “Baseline” specimens were obtained on three separate days before initiation of 
therapy. Thereafter, blood was obtained a t  monthly intervals, usually in conjunction with 
a personal interview, but occasionally through the mail. 
Aluminum nicotinate (Nicalex) was administered in fractional doses three times daily 
after meals. Changes in dosage were recommended only at three-month intervals. 
RESULTS 
E$ect on serum cholesterol level 
Seven patients received, as aluminum nicotinate, 1.5 gm. of nicotinic acid per 
day for three months, and then 3.0 gm. per day for three months. Figure 1 
illustrates the effect in each patient and the mean response of the group. The 
mean baseline value was 310 mg. per 100 ml. There was a fall to 303 mg. with 
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FIG. 1. Effect of aluminum nicotinate on the serum cholesterol level (mg./lOO ml.) in 7 
subjects. (Dosages in terms of nicotinic acid equivalents.) 
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the 1.5-gm. daily dosage and to 248 mg. with the 3.0-gm. dosage-a drop of 20 
per cent from the pretreatment level. The decrease was statistically significant 
for the larger dosage ( t  = 4.1; P < 0.01) but not for the smaller dosage (t = 1.11; 
P > 0.05). 
Table 1 contains the results for all patients who received aluminum nicotinate 
at  a given dosage level for at  least three months. In addition to the 7 patients 
who took the drug in both dosages, 4 patients took daily doses of 1.5 gm. only, 
and 3 patients took 3.0 gm. only. In the 11 patients studied with the 1.5-gm. dos- 
age, the serum cholesterol level remained unchanged in 2, rose in 2, and fell in 7. 
In 3 of the 10 patients studied with the 3.0-gm. dosage, the cholesterol level re- 
mained unchanged; in the other 7 it fell. 
Side efects 
Almost all patients noted occasional flushing of the face while receiving alu- 
minum nicotinate. With the larger dosage this tended to be more severe and 
prolonged, and frequently more generalized. Pruritus was extremely rare. 
Anorexia, nausea and vomiting occurred only rarely with the 1.5-gm. daily 
dosage, but was a problem to some of the women attempting to take 3.0 gm. 
daily. Intolerance to the drug altered the course of therapy in 10 women and 1 
man; the difficulty was gastric in all but 1 patient in whom the problem was a 
dermatitis which appeared in the “blush” areas. In general, patients tended to 
complain less about flushing and nausea after a few weeks of therapy. 
DISCUSSION 
Our findings indicate that 3.0 gm. of nicotinic acid per day in the form of alu- 
minum nicotinate will lower the serum cholesterol level impressively in most pa- 
tients (7 of 10 in our study) who can tolerate this dosage. A dosage of 1.5 gm. 
per day is much better tolerated, but is less effective. The reduction in serum 
cholesterol concentration is similar to that obtained with comparable doses of un- 
modified nicotinic acid (7, 8). 
Severe side effects necessitating interruption of treatment were limited almost 
to females. Only 1 woman out of 12 was able to maintain the higher dosage of 3.0 
gm. per day for three months. In contrast, only 1 male out of 13 dropped out of the 
study because of intolerance. The reason for this sex difference in drug tolerance 
is not apparent, but it constitutes a limitation to the effective use of aluminum 
nicotinate in the management of hypercholesterolemia in women. On the other 
hand, the drug is unusually well tolerated by men and has a potency similar to 
that reported for unmodified nicotinic acid. 
SUMMARY AND CONCLUSIONS 
In 25 patients with hypercholesterolemia, aluminum nicotinate in a dosage of 
3 gm. daily caused a drop of 20 per cent from the average pretreatment cho- 
lesterol level. When the drug was given in smaller amounts, the decrease in 
cholesterol concentration was not statistically significant. 
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Aluminum nicotinate is an effective blood cholesterol-lowering agent when 
Most women are unable to tolerate a dosage of this magnitude, primarily be- 
administered in a dosage of 3.0 gm. daily. 
cause of induced nausea, but the drug is well tolerated by men. 
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